RT Journal Article
T1 Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain
A1 Garcia-Carbonero, Rocio
A1 González Astorga, Beatriz
A1 Vidal Tocino, Rosario
A1 Contreras Toledo, Débora
A1 Pericay, Carles
A1 Fernandez Montes, Ana
A1 Falcó, Esther
A1 González Cordero, Marta
A1 Reina Zoilo, Juan José
A1 Alonso, Vicente
A1 Rodríguez Salas, Nuria
A1 Gil-Raga, Mireia
A1 Santos, Cristina
A1 Páez, David
A1 Anton-Pascual, Beatriz
A1 Aguilar, Fernando
A1 Morales, Pilar
AB Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). We aimed to describe the dMMR/MSI-H testing practice in patients with mCRC in Spanish centers.Multicenter, observational retrospective study that included patients newly diagnosed with mCRC or who progressed to a metastatic stage from early/localized stages.Three hundred patients were included in the study from May 2020 through May 2021, with a median age of 68 years, and two hundred twenty-five (75%) had stage IV disease at initial diagnosis; two hundred eighty-four patients received first-line treatment, and dMMR/MSI-H testing was performed in two hundred fifty-one (84%) patients. The results of the dMMR/MSI-H tests were available in 61 (24%) of 251 patients before the diagnosis of metastatic disease and in 191 (81%) of 236 evaluable patients for this outcome before the initiation of first-line treatment. Among the 244 patients who were tested for dMMR/MSI-H with IHC or PCR, 14 (6%) were MMR deficient. The most frequent type of first-line treatment was the combination of chemotherapy and biological agent, that was received by 71% and 50% of patients with MMR proficient and deficient tumors, respectively, followed by chemotherapy alone, received in over 20% of patients in each subgroup. Only 29% of dMMR/MSI-H tumors received first-line immunotherapy.Our study suggests that a high proportion of patients with mCRC are currently tested for dMMR/MSI-H in tertiary hospitals across Spain. However, there is still room for improvement until universal testing is achieved.Not applicable.
PB Springer
YR 2023
FD 2023-08-31
LK https://hdl.handle.net/20.500.13003/19917
UL https://hdl.handle.net/20.500.13003/19917
LA eng
NO Garcia-Carbonero R, González Astorga B, Vidal Tocino R, Contreras Toledo D, Pericay C, Fernández Montes A, et al. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. Clin Transl Oncol. 2023 Aug 31.
DS Docusalut
RD 23 sept. 2026